Rafael Holdings, Inc. (NYSE:RFL) Sees Significant Increase in Short Interest

Rafael Holdings, Inc. (NYSE:RFL) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 121,900 shares, an increase of 26.3% from the February 28th total of 96,500 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average daily volume of 36,200 shares, the short-interest ratio is currently 3.4 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Rafael stock. Geode Capital Management LLC raised its stake in Rafael Holdings, Inc. (NYSE:RFL) by 24.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 148,068 shares of the company’s stock after purchasing an additional 29,448 shares during the period. Geode Capital Management LLC owned 0.60% of Rafael worth $287,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 11.30% of the stock is currently owned by institutional investors and hedge funds.

Rafael Trading Up 2.2 %

Shares of RFL traded up $0.04 during midday trading on Wednesday, reaching $1.88. 25,589 shares of the stock were exchanged, compared to its average volume of 31,026. The company has a market capitalization of $46.84 million, a P/E ratio of -1.13 and a beta of 1.15. Rafael has a 52 week low of $1.29 and a 52 week high of $2.50. The company’s 50 day moving average is $1.97 and its two-hundred day moving average is $1.92.

Rafael (NYSE:RFL) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.06) EPS for the quarter. Rafael had a negative net margin of 5,707.03% and a negative return on equity of 53.71%. The business had revenue of $0.08 million during the quarter.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.